A phase III randomized trial of anastrozole and fulvestrant versus anastrozole or sequential anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: Final survival outcomes of SWOG S0226

被引：0
|
作者：
Mehta, Rita S.
Barlow, William E.
Albain, Kathy S.
Vandenberg, Ted A.
Dakhil, Shakher R.
Tirumali, Nagendra L.
Lew, Danika L.
Hayes, Daniel F.
Gralow, Julie R.
Linden, Hannah M.
Livingston, Robert B.
Hortobagyi, Gabriel N.
机构：
[1] UCIMC, Orange, CA USA
[2] SWOG Stat Ctr, Seattle, WA USA
[3] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA
[4] London Hlth Sci Ctr, London, ON, Canada
[5] Wichita Community Clin Oncol, Wichita, KS USA
[6] Northwest CCOP Northwest, Portland, OR USA
[7] Univ Michigan, Ann Arbor, MI 48109 USA
[8] Puget Sound Canc Consortium, Seattle, WA USA
[9] Univ Washington, Seattle, WA 98195 USA
[10] Univ Arizona, Arizona Canc, Tucson, AZ USA
[11] MD Anderson, Houston, TX USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD5-07
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Comparison of Fulvestrant 500 mg with Anastrozole as First-Line Treatment for Advanced Breast Cancer: Follow-Up Analysis from the 'FIRST' Study
    Robertson, J. F. R.
    Lindemann, J. P. O.
    Llombart-Cussac, A.
    Rolski, J.
    Felt, D.
    Dewar, J.
    Emerson, L.
    Dean, A.
    Ellis, M. J.
    CANCER RESEARCH, 2010, 70
  • [42] Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial ( Jan, 10.1200/JCO.24.00994, 2025)
    Robertson, John F. R.
    Shao, Zhimin
    Noguchi, Shinzaburo
    Bondarenko, Igor
    Panasci, Lawrence
    Singh, Sandeep
    Subramaniam, Shankar
    Ellis, Matthew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (08) : 1045 - 1045
  • [43] Independent central review of clinical benefit rates in FIRST: a Phase II comparison of fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for postmenopausal women with hormone receptor positive advanced breast cancer
    Lindemann, J. P. O.
    Robertson, J. F. R.
    Ellis, M. J.
    Menu, Y.
    Macpherson, E. J.
    Ghiorghiu, D. D. C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 282 - 282
  • [44] Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis
    Huang, Xiaoting
    Weng, Xiuhua
    Lin, Shen
    Liu, Yiwei
    Luo, Shaohong
    Wang, Hang
    Ming, Wai-kit
    Huang, Pinfang
    BMJ OPEN, 2020, 10 (08):
  • [45] Final Analysis of NCIC CTG MA.27: A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Hormone Receptor Positive Primary Breast Cancer
    Goss, P. E.
    Ingle, J. N.
    Chapman, J-A W.
    Ellis, M. J.
    Sledge, G. W.
    Budd, G. T.
    Rabaglio, M.
    Gelmon, K.
    Shepherd, L.
    Pritchard, K. I.
    CANCER RESEARCH, 2010, 70
  • [46] A phase II randomized trial of anastrozole (A) and fulvestrant (F) as consolidation therapy in postmenopausal women with advanced non-small cell lung cancer who have received first-line platinum-based chemotherapy with or without bevacizumab.
    McLaughlin, B. T.
    Land, S.
    Tarhini, A. A.
    Siegfried, J.
    Argiris, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Relationship between progression-free survival and overall survival in advanced breast cancer: a novel approach using first-line treatment data for fulvestrant 500 mg and anastrozole
    Ouwens, M.
    Grinsted, L. M.
    Telford, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [48] Anastrozole: A well established second-line agent and viable first-line option for postmenopausal women with advanced breast cancer
    不详
    Drugs & Therapy Perspectives, 2002, 18 (1) : 1 - 4
  • [49] Fulvestrant ('Faslodex®') versus anastrozole ('Arimidex®') for the treatment of advanced breast cancer in postmenopausal women -: safety update on the combined analysis of two multicenter trials.
    Jones, S
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 290 - 290
  • [50] FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer
    Ellis, M. J.
    Bondarenko, I.
    Trishkina, E.
    Dvorkin, M.
    Panasci, L.
    Manikhas, A.
    Shparyk, Y.
    Cardona-Huerta, S.
    Cheung, K-L.
    Philco-Salas, M. J.
    Ruiz-Borrego, M.
    Shao, Z.
    Noguchi, S.
    Grinsted, L. M.
    Fazal, M.
    Stuart, M.
    Robertson, J. F.
    ANNALS OF ONCOLOGY, 2016, 27
12345